3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
5
Thoracic
4
Genitourinary
3
Gastrointestinal
3
Head & Neck
2
Other solid neoplasm
1
Lymphoid
1
Gynecologic
1
Conditions
Lymphoma, Large B-Cell, Diffuse
73
Lymphoma
66
Hodgkin Disease
52
Lymphoma, Non-Hodgkin
48
Recurrence
24
Lymphoma, Extranodal NK-T-Cell
19
Lymphoma, T-Cell, Peripheral
18
Lymphoma, Follicular
18
Lymphoma, Mantle-Cell
14
Neoplasms
13
Lymphoma, T-Cell
13
Precursor Cell Lymphoblastic Leukemia-Lymphoma
12
Lymphoma, Large-Cell, Anaplastic
11
Lymphoma, B-Cell
11
Lymphoma, T-Cell, Cutaneous
10
Leukemia, Lymphocytic, Chronic, B-Cell
10
Burkitt Lymphoma
10
Mycosis Fungoides
9
Lymphoma, Large-Cell, Immunoblastic
9
Lymphoma, B-Cell, Marginal Zone
9
Immunoblastic Lymphadenopathy
9
Sezary Syndrome
8
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
6
Pancreatic Neoplasms
6
Neoplasm Metastasis
5
Leukemia
5
Breast Neoplasms
5
Waldenstrom Macroglobulinemia
4
Sarcoma
4
Lung Neoplasms
4
Interventions
pembrolizumab
5
Gemcitabine
1
Brentuximab Vedotin
1
Bendamustine Hydrochloride
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Parkinson Disease 4, Autosomal Dominant Lewy Body
×
Gemcitabine
×
Lymphoid
×
Clear all
NCT05508867
2026-01-20
MK-4280A-008
Merck Sharp & Dohme LLC
Phase 2
Completed
203 enrolled